Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IT stocks lead the gainers
Wed, 23 Jul 11:30 am

After opening firm, the Indian stock markets have given up most of the gains in morning session. Among the sectoral indices, maximum buying activity is witnessed in Software and Banking stocks, while Energy and FMCG stocks are at the receiving end.

The BSE-Sensex is trading up 39 points. The NSE-Nifty is trading up 5 points. The BSE Mid Cap index is trading down 0.2% and the BSE Small Cap index is trading down 0.6%. The rupee is trading at 60.16 to the US dollar.

Private banking stocks are trading mixed today. While City Union Bank is leading the gainers; ING Vysya Bank is leading the losers. Axis Bank, India's third largest private sector bank, has announced results for 1QFY15. The bank's Net Interest Income (NII) grew 15.5% YoY while the net profit grew by 18.3% YoY. Despite a 45.7% YoY fall in provisions, the bottomline was hampered due to higher operating costs as well as lower non-interest income. Non-interest income was down 5% YoY, while operating expenses were up by 16.8% YoY. The asset quality numbers were slightly below par. In absolute terms, gross non-performing assets (NPAs) rose 39% YoY and net NPAs rose 41% YoY. Axis Bank is trading down 1.6% today.

Indian pharma stocks are trading mixed with, Dishman pharma and Indoco remedies leading among the pack of losers while Natco pharma and Wockhardt Ltd are the leading gainers. As per the financial daily, the European pharma company GlaxoSmithKline (GSK) is looking to divest some of its mature products in its portfolio. Various generic companies including India based Lupin Ltd is planning to bid for these brands, as GSK has put some of its older products on auction. GSK is selling of various off-patent drugs which are marketed in North America and Western Europe. These drugs have total annual sales of around US$ 1.7 bn. The portfolio of drugs offered for sale includes antidepressant Paxil, migraine treatment Imitrex, Zantac for stomach acid and Zofran for nausea. While there has been no confirmation by Lupin on this aspect as of now. However, as Lupin has been looking for acquisition of lucrative brands since some time, there is fair chance of Lupin bidding for the GSK brands.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT stocks lead the gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.